Researchers ID mechanism behind severe ABCB11 mutations in PFIC2
Severe mutations in the ABCB11 gene cause progressive familial intrahepatic cholestasis type 2 (PFIC2) by destabilizing the resulting BSEP protein in a specific region,…
News
Phase 3 trial of lanifibranor for MASH completes enrollment
Enrollment is complete for a Phase 3 clinical trial testing lanifibranor in people with metabolic dysfunction-associated steatohepatitis (MASH) — a severe type of fatty…
Bile acid levels may predict outcome of Kasai surgery for biliary atresia
Measuring the blood levels of bile acids, the main component of the digestive fluid bile, can help predict key clinical outcomes for babies with…
Zetomipzomib brings steroid-sparing remission in autoimmune hepatitis
Six months of treatment with Kezar Life Sciences‘ candidate zetomipzomib led to biochemical disease remission for adults with treatment-resistant autoimmune hepatitis, enabling them…
Nebokitug shows sustained benefits for moderate, advanced PSC
A year of treatment with Chemomab Therapeutics’s candidate nebokitug reduces key disease biomarkers and the occurrence of clinical events that reflect disease progression among…
Liver tissue analysis may help ID, distinguish PFIC types: Study
Analyzing the presence of different proteins in liver tissue under a microscope can be used to help diagnose progressive familial intrahepatic cholestasis (PFIC) and…
MASLD tied to higher mortality risk from nearly every cause
Compared with the general population, the risk of death is nearly twice as high in people with metabolic dysfunction-associated steatotic liver disease (MASLD), a form…
Livmarli approved in Japan as itching treatment for Alagille, PFIC
Livmarli (maralixibat) has been approved in Japan for the treatment of itching in people with Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC),…
Phase 1 trial of gene-editing therapy for hepatitis B cleared in US
Precision Biosciences has been given the go-ahead to expand a Phase 1 clinical trial testing PBGENE-HBV, its gene-editing therapy for chronic hepatitis…
2nd-line PBC treatment options call for personalized care: Analysis
Among second-line treatments for primary biliary cholangitis (PBC), Iqirvo (elafibranor) may work better than Livdelzi (seladelpar) at reducing markers of liver damage, while Livdelzi…
